Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).

被引：0
|
作者：
Bradford, Diana
Whitcomb, Patricia
Dombi, Eva
Chen, Alice P.
Baldwin, Andrea
Wolters, Pamela
Martin, Staci
Glod, John
Derdak, Joanne
Coyne, Geraldine Helen O'Sullivan
Cowen, Edward W.
Holmblad, Marielle
Trepel, Jane
Wood, Bradford J.
Paul, Scott M.
Clapp, Wade
Johnson, Gary L.
Rubinstein, Larry
Doyle, L. Austin
Widemann, Brigitte C.
机构：
[1] Childrens Natl Med Ctr, Washington, DC 20010 USA
[2] NCI, Bethesda, MD 20892 USA
[3] NCI, Pediat Oncol Branch, Bethesda, MD 20892 USA
[4] NCI, Early Clin Trials Dev Program, NIH, Bethesda, MD 20892 USA
[5] NCI, NIH, Bethesda, MD 20892 USA
[6] Early Clin Trials Dev Program, Bethesda, MD USA
[7] NCI, Dermatol Branch, Ctr Canc Res, Bethesda, MD 20892 USA
[8] NCI, Clin Res Directorate, Clin Monitoring Res Program, Leidos Biomed Research Inc, Frederick, MD 21701 USA
[9] NCI, Dev Therapeut Branch, Ctr Canc Res, Bethesda, MD 20892 USA
[10] NCI, Ctr Intervent Oncol, NIH, Bethesda, MD 20892 USA
[11] NCI, Rehabil Med Dept, Ctr Clin, Bethesda, MD 20892 USA
[12] Indiana Univ, Sch Med, Indianapolis, IN USA
[13] Univ N Carolina, Sch Med, Chapel Hill, NC 27515 USA
[14] OD, Biometr Res Program, Div Canc Treatment & Diag, Bethesda, MD USA
[15] NCI, Invest Drug Branch, Canc Therapeut Evaluat Program, Bethesda, MD 20892 USA
[16] NCI, Ctr Canc Res, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS2596
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2596
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 1 study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
    Widemann, Brigitte C.
    Marcus, Leigh Jessica
    Fisher, Michael J.
    Weiss, Brian D.
    Kim, AeRang
    Dombi, Eva
    Baldwin, Andrea
    Whitcomb, Patricia
    Martin, Staci
    Gillespie, Andrea
    Doyle, Austin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] SELUMETINIB (AZD6244) HYDROGEN SULFATE, A MEK1/2 INHIBITOR, IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PNS): A PHASE I STUDY
    Fisher, Michael J.
    Marcus, Leigh
    Weiss, Brian
    Kim, AeRang
    Dombi, Eva
    Baldwin, Andrea
    Whitcomb, Patricia
    Martin, Staci
    Gillespie, Andrea
    Doyle, Austin
    Widemann, Brigitte C.
    NEURO-ONCOLOGY, 2014, 16 : 129 - 129
  • [3] Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Coyne, Geraldine Helen O'Sullivan
    Gross, Andrea M.
    Dombi, Eva
    Tibery, Cecilia
    Carbonell, Amanda
    Takebe, Naoko
    Derdak, Joanne
    Pichard, Dominique
    Srivastava, Apurva K.
    Herrick, William
    Parchment, Ralph E.
    Martin, Staci
    Wolters, Pamela
    Whitcomb, Patricia
    Rubinstein, Lawrence
    Doroshow, James H.
    Chen, Alice P.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Phase II Study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Gross, Andrea M.
    Baldwin, Andrea
    Dombi, Eva
    Wolters, Pamela
    Whitcomb, Patricia
    Holmblad, Marielle
    Martin, Staci
    Fisher, Michael J.
    Kim, AeRang
    Weiss, Brian D.
    Paul, Scott M.
    Clapp, Wade
    Farrell, Kathleen
    Smith, Michaele
    Fontana, Joseph
    Brofferio, Alessandra
    Steinberg, Seth M.
    Doyle, Laurence A.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).
    Gross, Andrea M.
    Wolters, Pamela
    Baldwin, Andrea
    Dombi, Eva
    Fisher, Michael J.
    Weiss, Brian D.
    Kim, AeRang
    Blakeley, Jaishri O'Neill
    Whitcomb, Patricia
    Holmblad, Marielle
    Martin, Staci
    Roderick, Marie Claire
    Paul, Scott M.
    Therrien, Janet
    Heisey, Kara
    Doyle, Austin
    Smith, Malcolm A.
    Glod, John
    Steinberg, Seth M.
    Widemann, Brigitte C.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
    Gross, Andrea
    Wolters, Pamela
    Baldwin, Andrea
    Dombi, Eva
    Fisher, Michael J.
    Weiss, Brian
    Kim, AeRang
    Blakeley, Jaishri
    Whitcomb, Patricia
    Holmblad, Marielle
    Maritin, Staci
    Roderick, Marie Claire
    Paul, Scott M.
    Therrien, Janet
    Heisey, Kara
    Doyle, Austin
    Smith, Malcolm
    Glod, John
    Steinberg, Seth
    Widemann, Brigitte C.
    NEURO-ONCOLOGY, 2018, 20 : 143 - 144
  • [7] Phase II Trial of the MEK 1/2 inhibitor selumetinib (AZD6344, ARRY-142886 hydrogen sulphate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN)
    Coyne, Geraldine O'Sullivan
    Gross, Andrea
    Dombi, Eva
    DeSanto, Jennifer
    Carbonell, Amanda
    Derdak, Joanne
    Pichard, Dominique
    Wood, Brad
    Tibery, Cecilia
    Wolters, Pam
    Whitcomb, Trish
    Martin, Staci
    Bradford, Diana
    Srivastava, Apurva
    Herrick, William
    Parchment, Ralph
    Heisey, Kara
    Doyle, Austin
    Takebe, Naoko
    Doroshow, James H.
    Chen, Alice P.
    Widemann, Brigitte
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [8] Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial
    Gross, Andrea M.
    Coyne, Geraldine O'Sullivan
    Dombi, Eva
    Tibery, Cecilia
    Herrick, William G.
    Martin, Staci
    Angus, Steven P.
    Shern, Jack F.
    Rhodes, Steven D.
    Foster, Jared C.
    Rubinstein, Larry V.
    Baldwin, Andrea
    Davis, Christopher
    Dixon, Shelley A. H.
    Fagan, Margaret
    Ong, Mary Jane
    Wolters, Pamela L.
    Tamula, Mary Anne
    Reid, Olivia
    Sankaran, Hari
    Fang, Fang
    Govindharajulu, Jeevan Prasaad
    Browne, Alice T.
    Kaplan, Rosandra N.
    Heisey, Kara
    On, Thomas J.
    Xuei, Xiaoling
    Zhang, Xiyuan
    Johnson, Barry C.
    Parchment, Ralph E.
    Clapp, D. Wade
    Srivastava, Apurva K.
    Doroshow, James H.
    Chen, Alice P.
    Widemann, Brigitte C.
    NATURE MEDICINE, 2025, 31 (01) : 105 - 115
  • [9] A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
    Holkova, Beata
    Zingone, Adriana
    Kmieciak, Maciej
    Bose, Prithviraj
    Badros, Ashraf Z.
    Voorhees, Peter M.
    Baz, Rachid
    Korde, Neha
    Lin, Hui-Yi
    Chen, Jin-Qiu
    Herrmann, Michelle
    Xi, Liqiang
    Raffeld, Mark
    Zhao, Xiuhua
    Wan, Wen
    Tombes, Mary Beth
    Shrader, Ellen
    Weir-Wiggins, Caryn
    Sankala, Heidi
    Hogan, Kevin T.
    Doyle, Austin
    Annunziata, Christina M.
    Wellons, Martha
    Roberts, John D.
    Sullivan, Daniel
    Landgren, Ola
    Grant, Steven
    CLINICAL CANCER RESEARCH, 2016, 22 (05) : 1067 - 1075
  • [10] PHASE I TRIAL OF SORAFENIB IN CHILDREN WITH NEUROFIBROMATOSIS TYPE I (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)
    Kim, A.
    Dombi, E.
    Tepas, K.
    Fox, E.
    Balis, F. M.
    Korf, B.
    Widemann, B. C.
    NEURO-ONCOLOGY, 2010, 12 (06) : II42 - II42
12345